Related Experiment Video
Updated: Oct 6, 2025

Nephrotoxin Microinjection in Zebrafish to Model Acute Kidney Injury
Published on: July 17, 2016
Uremic Toxins and Protein-Bound Therapeutics in AKI and CKD: Up-to-Date Evidence
Jia-Huang Chen1, Chih-Kang Chiang1,2,3,4
1Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan.
Abstract:
Uremic toxins are defined as harmful metabolites that accumulate in the human body of patients whose renal function declines, especially chronic kidney disease (CKD) patients. Growing evidence demonstrates the deteriorating effect of uremic toxins on CKD progression and CKD-related complications, and removing uremic toxins in CKD has become the conventional treatment in the clinic. However, studies rarely pay attention to uremic toxin clearance in the early stage of acute kidney injury (AKI) to prevent progression to CKD despite increasing reports demonstrating that uremic toxins are correlated with the severity of injury or mortality. This review highlights the current evidence of uremic toxin accumulation in AKI and the therapeutic value to prevent CKD progression specific to protein-bound uremic toxins (PBUTs).
Insights
Uremic toxins accumulate in acute kidney injury (AKI), worsening outcomes. Clearing these toxins, especially protein-bound uremic toxins (PBUTs), may prevent chronic kidney disease (CKD) progression.
Area of Science:
- Nephrology
- Toxicology
- Biochemistry
Background:
- Uremic toxins are harmful metabolites accumulating with declining renal function, particularly in chronic kidney disease (CKD).
- Current CKD treatment focuses on removing uremic toxins, but their role in acute kidney injury (AKI) is understudied.
- Uremic toxin accumulation in AKI correlates with injury severity and mortality.
Purpose of the Study:
- To review the evidence of uremic toxin accumulation in AKI.
- To highlight the therapeutic potential of uremic toxin clearance in preventing CKD progression after AKI.
- To specifically focus on protein-bound uremic toxins (PBUTs).
Main Methods:
- Literature review of existing studies on uremic toxins in AKI and CKD.
- Analysis of evidence linking uremic toxin levels to AKI severity and outcomes.
- Examination of therapeutic strategies for uremic toxin removal in AKI.
Main Results:
- Uremic toxins accumulate significantly in AKI patients.
- Early uremic toxin clearance may mitigate AKI severity.
- PBUTs are implicated in AKI progression to CKD.
Conclusions:
- Uremic toxin accumulation is a critical factor in AKI.
- Targeting uremic toxins, particularly PBUTs, in AKI offers a potential strategy to prevent CKD progression.
- Further research is needed on early intervention for uremic toxin clearance in AKI.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury I: Introduction
Chronic Kidney Disease III: Interprofessional Care

